Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

André Frenk

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
European Heart Journal|December 13, 2023
Randomized controlled trials remain underutilizedGeorge C M Siontis, André Frenk, Stephan Windecker
Trials|September 10, 2020
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trialStefano Barco, Roland Bingisser, Giuseppe Colucci, et al.
International Journal of Cardiology|June 2, 2017
Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and designDaniel Tobler, Judith Bouchardy, Engel Reto, et al.
European Heart Journal|August 28, 2023
Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortiumGeorge C M Siontis, Bernadette Coles, Jonas D Häner, et al.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
European Journal of Heart Failure|June 2, 2023
Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVEMatthias Greutmann, Daniel Tobler, Reto Engel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
European Heart Journal|December 13, 2023
Randomized controlled trials remain underutilizedGeorge C M Siontis, André Frenk, Stephan Windecker
Trials|September 10, 2020
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trialStefano Barco, Roland Bingisser, Giuseppe Colucci, et al.
International Journal of Cardiology|June 2, 2017
Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rational and designDaniel Tobler, Judith Bouchardy, Engel Reto, et al.
European Heart Journal|August 28, 2023
Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD consortiumGeorge C M Siontis, Bernadette Coles, Jonas D Häner, et al.
The Lancet. Haematology|July 2, 2022
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trialStefano Barco, Davide Voci, Ulrike Held, et al.
European Journal of Heart Failure|June 2, 2023
Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVEMatthias Greutmann, Daniel Tobler, Reto Engel, et al.
Pageof 1